Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 3, 2002, Pages 187-192

  Zangari, Maurizio ^a   Saghafifar, F ^a   Anaissie, E ^a   Badros, A ^a   Desikan, R ^a   Fassas, A ^a   Mehta, P ^a   Morris, C ^a   Toor, A ^a   Whitfield, D ^a   Siegel, E ^a   Barlogie, B ^a   Fink, L ^a   Tricot, G ^a  

^a Department of Medicine ^*  (United States)

Author keywords

Activated protein C resistance; Myeloma; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; THALIDOMIDE; VINCRISTINE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERCOAGULABILITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION TESTS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FACTOR V; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LIFE TABLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK; THALIDOMIDE; THROMBOPHILIA; VENOUS THROMBOSIS; VINCRISTINE;

EID: 0036526384     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200204000-00003     Document Type: Article

References (19)

1. Anticoagulant protein C pathway defective in majority of thrombophilic patients
2. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism
3. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
4. Prognosis of cancers associated with venous thromboembolism
5. Total therapy with tandem transplants for newly diagnosed multiple myeloma
6. Increased risk of deep vein thrombosis in multiple myeloma patients receiving thalidomide in combination with chemotherapy
7. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa
8. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria
9. Antiphospholipid antibody syndrome: New insights on thrombogenic mechanisms
10. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomized cross-over study
11. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway
12. Factor V Cambridge: A new mutation (Arg306 → thr) associated with resistance to activated protein C
13. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese
14. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
15. Resistance to activated protein C as a basis for venous thrombosis
16. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
17. Activated protein C resistance in ischemic stroke not due to factor V arginine506 → glutamine mutation
18. 506 mutation in unselected oncology patients
19. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis